Targeting Interleukin-1β and Inflammation in Lung Cancer

Overview

Journal Biomark Res

Publisher Biomed Central

Date 2022 Jan 28

PMID 35086565

Authors

Jun Zhang

Nirmal Veeramachaneni

Affiliations

Soon will be listed here.

Abstract

Inflammation is a process that protects organs against various potentially harmful stimuli and enables repair. Dysregulated inflammation, however, damages tissues and leads to disease, including cancer. Cancer-related inflammation is characterized by cytokine production, leukocyte infiltration, angiogenesis, and tissue remodeling-all critical processes in modulating the tumor microenvironment (TME). The TME is known to play a key role in tumor progression, and targeting its immune component to achieve a better anti-tumor response is the basis of immunotherapy. Despite the critical role cytokines play in the TME and tumor progression, there is currently only one therapy approved by the FDA that directly involves cytokine signaling: human recombinant interleukin-2 protein, aldesleukin. The recent Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) trial evaluated the use of anti-interleukin-1β therapy in atherosclerotic disease; however, it also revealed interleukin-1β (IL-1β) blockade with canakinumab led to a significantly lower incidence of lung cancer. This has opened a promising new avenue for lung cancer therapy, and strategies using anti-IL-1β therapy alone or in combination with chemotherapy and/or immune checkpoint blockade are currently being evaluated in several clinical trials.

Citing Articles

Increased inflammatory signature in myeloid cells of non-small cell lung cancer patients with high clonal hematopoiesis burden.

Sim H, Park H, Park G, Kim Y, Park W, Lee S Elife. 2024; 13.

PMID: 39641768 PMC: 11623926. DOI: 10.7554/eLife.96951.

The Role of Exhaled Breath Condensate in Chronic Inflammatory and Neoplastic Diseases of the Respiratory Tract.

Kita K, Gawinowska M, Chelminska M, Niedoszytko M Int J Mol Sci. 2024; 25(13).

PMID: 39000502 PMC: 11242091. DOI: 10.3390/ijms25137395.

Combination of percutaneous thermal ablation and adoptive Th9 cell transfer therapy against non-small cell lung cancer.

Pan H, Tian Y, Pei S, Yang W, Zhang Y, Gu Z Exp Hematol Oncol. 2024; 13(1):52.

PMID: 38760861 PMC: 11100251. DOI: 10.1186/s40164-024-00520-8.

Clinical significance of PNO1 as a novel biomarker and therapeutic target of hepatocellular carcinoma.

Roy S, Srivastava S, McCance C, Shrivastava A, Morvant J, Shankar S J Cell Mol Med. 2024; 28(9):e18295.

PMID: 38722284 PMC: 11081011. DOI: 10.1111/jcmm.18295.

Senescence-associated secretory phenotype (SASP) and uterine fibroids: Association with PD-L1 activation and collagen deposition.

Saad E, Michel R, Borahay M Ageing Res Rev. 2024; 97:102314.

PMID: 38670462 PMC: 11181954. DOI: 10.1016/j.arr.2024.102314.

References

Hinshaw D, Shevde L . The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019; 79(18):4557-4566. PMC: 6744958. DOI: 10.1158/0008-5472.CAN-18-3962. View

Kim J, Koh Y, Kim D, Ahn Y, Kim T, Han S . Clinical Implications of VEGF, TGF-β1, and IL-1β in Patients with Advanced Non-small Cell Lung Cancer. Cancer Res Treat. 2014; 45(4):325-33. PMC: 3893330. DOI: 10.4143/crt.2013.45.4.325. View

Bojinca V, Janta I . Rheumatic diseases and malignancies. Maedica (Bucur). 2013; 7(4):364-71. PMC: 3593292. View

Lu H, Ouyang W, Huang C . Inflammation, a key event in cancer development. Mol Cancer Res. 2006; 4(4):221-33. DOI: 10.1158/1541-7786.MCR-05-0261. View

Fridman W, Zitvogel L, Sautes-Fridman C, Kroemer G . The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017; 14(12):717-734. DOI: 10.1038/nrclinonc.2017.101. View

Huang J, Lan X, Wang T, Lu H, Cao M, Yan S . Targeting the IL-1β/EHD1/TUBB3 axis overcomes resistance to EGFR-TKI in NSCLC. Oncogene. 2019; 39(8):1739-1755. DOI: 10.1038/s41388-019-1099-5. View

Wu T, Xu K, Martinek J, Young R, Banchereau R, George J . IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer. Cancer Res. 2018; 78(18):5243-5258. PMC: 6391892. DOI: 10.1158/0008-5472.CAN-18-0413. View

Becht E, Giraldo N, Lacroix L, Buttard B, Elarouci N, Petitprez F . Erratum to: Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016; 17(1):249. PMC: 5134277. DOI: 10.1186/s13059-016-1113-y. View

Jiang Y, Chen M, Nie H, Yuan Y . PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother. 2019; 15(5):1111-1122. PMC: 6605868. DOI: 10.1080/21645515.2019.1571892. View

10.

Ridker P, MacFadyen J, Thuren T, Everett B, Libby P, Glynn R . Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017; 390(10105):1833-1842. DOI: 10.1016/S0140-6736(17)32247-X. View

11.

Millares L, Barreiro E, Cortes R, Martinez-Romero A, Balcells C, Cascante M . Tumor-associated metabolic and inflammatory responses in early stage non-small cell lung cancer: Local patterns and prognostic significance. Lung Cancer. 2018; 122:124-130. DOI: 10.1016/j.lungcan.2018.06.015. View

12.

Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J . Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2018; 9(6):7204-7218. PMC: 5805548. DOI: 10.18632/oncotarget.23208. View

13.

Gelfo V, Mazzeschi M, Grilli G, Lindzen M, Santi S, DUva G . A Novel Role for the Interleukin-1 Receptor Axis in Resistance to Anti-EGFR Therapy. Cancers (Basel). 2018; 10(10). PMC: 6210663. DOI: 10.3390/cancers10100355. View

14.

Shiels M, Pfeiffer R, Hildesheim A, Engels E, Kemp T, Park J . Circulating inflammation markers and prospective risk for lung cancer. J Natl Cancer Inst. 2013; 105(24):1871-80. PMC: 3888091. DOI: 10.1093/jnci/djt309. View

15.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

16.

Lust J, Lacy M, Zeldenrust S, Witzig T, Moon-Tasson L, Dinarello C . Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma. Am J Hematol. 2016; 91(6):571-4. DOI: 10.1002/ajh.24352. View

17.

Qian S, Golubnitschaja O, Zhan X . Chronic inflammation: key player and biomarker-set to predict and prevent cancer development and progression based on individualized patient profiles. EPMA J. 2019; 10(4):365-381. PMC: 6882964. DOI: 10.1007/s13167-019-00194-x. View

18.

McLoed A, Sherrill T, Cheng D, Han W, Saxon J, Gleaves L . Neutrophil-Derived IL-1β Impairs the Efficacy of NF-κB Inhibitors against Lung Cancer. Cell Rep. 2016; 16(1):120-132. PMC: 4927403. DOI: 10.1016/j.celrep.2016.05.085. View

19.

Bremnes R, Al-Shibli K, Donnem T, Sirera R, Al-Saad S, Andersen S . The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. J Thorac Oncol. 2010; 6(4):824-33. DOI: 10.1097/JTO.0b013e3182037b76. View

20.

Mantovani A, Dinarello C, Molgora M, Garlanda C . Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity. Immunity. 2019; 50(4):778-795. PMC: 7174020. DOI: 10.1016/j.immuni.2019.03.012. View